Genetic Signatures Exhibiting at 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid Spain

 

eccmid-2018

Genetic Signatures’ are proud to announce we will be exhibiting at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 21-24 April 2018 in Madrid, Spain.

It is a pleasure to announce that Medical Scientist, Elaine McGrath from the University Hospital, Galway, has been selected to present a scientific poster titled “Evaluation of the EasyScreenTM CPO 3baseTM real-time PCR assay for detection of Carbapenemase genes directly from rectal swabs.”

The poster will highlight Genetic Signatures’ proprietary 3base™ technology and upcoming EasyScreenTM ESBL/CPO detection kit, which simultaneously identifies 16 of the most common Anti-microbial resistant pathogen strains.

Abstract No: 6682

Session type: Paper Poster Session #P2322

Session name: Detection of carbapenem resistance

Session date: 24/04/2018

Session time: 12:30h – 13:30h CEST

Genetic Signatures will also exhibit the EasyScreen™  products for the detection of infectious diseases, including kits for diagnosing Enteric bacterial, viral and protozoan pathogens, Respiratory pathogens, Sexual Health pathogens, Tropical disease pathogens, and Meningitis.

Visit Genetic Signatures at Booth #83 at ECCMID 2018 for more information. Click here to visit ECCMID 2018 


About ESBL and CPO: ESBLs are enzymes that mediate resistance to extended-spectrum (third generation) cephalosporins and monobactams but do not affect cephamycins or carbapenems. The presence of an ESBL-producing organism in a clinical infection can result in treatment failure if one of the above classes of drugs is used. ESBLs can be difficult to detect because they have different levels of activity against various cephalosporins. Thus, the choice of which antimicrobial agents to test is critical. 1

 CPO or CRE, which stands for carbapenemase producing organisms or carbapenem-resistant Enterobacteriaceae organisms, are a family of germs that are difficult to treat because they have high levels of resistance to antibiotics. Klebsiella species and Escherichia coli (E. coli) are examples of Enterobacteriaceae, a normal part of the human gut bacteria, that can become carbapenem-resistant. Types of CRE are sometimes known as KPC (Klebsiella pneumoniae carbapenemase) and NDM (New Delhi Metallo-beta-lactamase). KPC and NDM are enzymes that break down carbapenems and make them ineffective. Both of these enzymes, as well as the enzyme VIM (Verona Integron-Mediated Metallo-β-lactamase) have also been reported in Pseudomonas.

Healthy people usually do not get CRE infections – they usually happen to patients in hospitals, nursing homes, and other healthcare settings. Patients whose care requires devices like ventilators (breathing machines), urinary (bladder) catheters, or intravenous (vein) catheters, and patients who are taking long courses of certain antibiotics are most at risk for CRE infections.

Some CRE bacteria have become resistant to most available antibiotics. Infections with these germs are very difficult to treat, and can be deadly-one report cites they can contribute to death in up to 50% of patients who become infected.2

About the EasyScreen™ Antibiotic Resistance Detection Kit: The EasyScreen™ Antibiotic Resistance Detection Kit detects the most common resistant markers. ESBL and CPO targets that are detected are β –Lactamases TEM, SHV, CTX-M, CMY, DHA, OXA-48 like, OXA- 23 like, OXA-51 like, GES, MCR-1,IMI,SME, , New Delhi Metallo- β –Lactamases (NDM), Klebsiella pneumoniae carbapenemase (KPC), Metallo- β –Lactamases VIM, Metallo- β –Lactamases IMP

References:  

  1. https://www.cdc.gov/hai/settings/lab/lab_esbl.html
  2. https://www.cdc.gov/hai/organisms/cre/index.html

About ECCMID: The 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) is one of the largest European Infectious diseases meetings. The congress provides a forum for the world’s leading experts who come together to discuss the latest developments in diseases, infection control, and clinical microbiology.